AstraZeneca bolsters heart and kidney business with $1.8 billion deal with CinCor

AZN shares slip 1% on Monday Farxiga-baxdrostat combination could expand franchise – AZN exec Falling valuations of biotech companies could boost deal-making Jan 9 (Reuters) – AstraZeneca (AZN.L) said on Monday it has reached an agreement to buy U.S. drug developer CinCor Pharma Inc (CINC.O) for up to $1.8 billion to boost its stock of … Read more